Pharmacytimes: Condition Center: Acute Coronary Syndrome Acute Coronary Syndrome en-us Sat, 28 Mar 2015 12:39:07 UTC Sat, 28 Mar 2015 12:39:07 UTC Adherence to Guidelines Doesn’t Ensure ACS Inpatient Safety Many regulatory and professional organizations monitor hospitals for compliance to treatment guidelines, equating the use of evidence-based processes to high-quality care. Wed, 11 Mar 2015 03:00:00 UTC Room for Improvement in Acute Coronary Syndrome Treatment Antithrombotic therapy is an essential element of treatment after patients experience acute coronary syndrome. Fortunately, prescribers can draw from a considerably larger selection of antithrombotics than ever before, as prasugrel, ticagrelor, fondaparinux, and bivalirudin have joined warfarin, unfractionated heparin, and the low molecular weight heparins in evidence-based guidelines. Thu, 15 Jan 2015 02:00:55 UTC AstraZeneca Antiplatelet Drug Prevents Cardiovascular Events After Heart Attack AstraZeneca announced today that a study evaluating ticagrelor (Brilinta) for the secondary prevention of atherothrombotic events in patients with a history of heart attacks has met its primary efficacy endpoint. Wed, 14 Jan 2015 06:23:01 UTC Women with Celiac Disease Shouldn’t Fret Over Fertility Women with celiac disease do not report more fertility problems than the general population. Tue, 09 Dec 2014 02:00:37 UTC Reducing Acute Coronary Syndrome Readmission Rates Joe Moose, PharmD, of Moose Pharmacy, discusses the role of the pharmacist in prevention and reducing readmissions among acute coronary syndrome patients. Sat, 06 Dec 2014 06:00:57 UTC Acute Coronary Syndrome in Women: A 10-Year Review As pharmacists’ ability to tease out more comprehensive information from clinical trials has increased, it has become evident that social and biologic factors interact to produce paradoxical health differences between men and women, especially on cardiovascular outcomes. Sat, 06 Dec 2014 02:02:01 UTC Readmission Rates for Acute Coronary Syndrome Joe Moose, PharmD, of Moose Pharmacy, discusses rising readmission rates among patients with acute coronary syndrome. Fri, 05 Dec 2014 05:57:48 UTC Barriers in Acute Coronary Syndrome Drug Adherence Joe Moose, PharmD, of Moose Pharmacy, discusses the unique challenges to adherence that acute coronary syndrome patients face. Thu, 04 Dec 2014 05:56:21 UTC Care Transitions for Acute Coronary Syndrome Patients Joe Moose, PharmD, of Moose Pharmacy, discusses the role of the pharmacist in care transitions for acute coronary syndrome patients. Wed, 03 Dec 2014 05:55:01 UTC Caring for Acute Coronary Syndrome Patients Joe Moose, PharmD, of Moose Pharmacy, discusses how pharmacists can care for patients with acute coronary syndrome. Tue, 02 Dec 2014 05:51:27 UTC Can Polypills Better Prevent Cardiovascular Disease? The pros and cons of fixed-dose combination therapy first became major media news in 2001 when a World Health Organization expert panel proposed polypill use for noncommunicable diseases. Fri, 28 Nov 2014 03:01:01 UTC Predicting Poor Outcomes in Myocardial Infarction Researchers identify a potential marker for poor prognosis after acute myocardial infarction. Thu, 06 Nov 2014 05:03:01 UTC Selecting Antiplatelet Agents for Diabetics With Acute Coronary Syndrome Many cardiologists and pharmacists are concerned about clopidogrel, especially when it is prescribed for patients with diabetes. Fri, 17 Oct 2014 01:16:43 UTC Starting Statins Soon After Acute Coronary Syndrome Leads to Less Unstable Angina Patients who receive statins soon after acute coronary syndrome are 24% less likely to experience unstable angina after 4 months. Thu, 11 Sep 2014 12:14:01 UTC Statins After ACS: Continue Therapy for at Least 5 Years Patients continue to benefit from high-dose atorvastatin therapy for at least 5 years after acute coronary syndrome, according to a new study. Tue, 19 Aug 2014 08:15:49 UTC Acute Coronary Syndrome: The Sad Facts in Black and White Study finds that black patients who visit the emergency department with ACS have more symptoms and higher symptom severity than white patients. Thu, 24 Jul 2014 01:03:45 UTC Prasugrel or Clopidogrel in ACS: A Head-to-Head Study A recent study examines the comparative efficacy of prasugrel and clopidogrel in the treatment of patients who underwent percutaneous coronary intervention. Mon, 30 Jun 2014 02:17:39 UTC Treating Depression After ACS: Seeking an Optimal Treatment Duration Patients who were treated for persistent depression after an acute coronary syndrome experienced improved outcomes during treatment, but worsened outcomes after treatment ended. Wed, 04 Jun 2014 02:29:40 UTC High-Dose Statins: Protecting the Heart, Damaging the Kidneys? Probably Not An analysis of 2 randomized trials of statin therapy for patients enrolled after an acute coronary syndrome finds that high-dose statins do not increase the risk of kidney injury. Fri, 09 May 2014 06:38:40 UTC Depression Identified as a Risk Factor for Poor Prognosis After ACS A scientific statement from the American Heart Association concludes that depression should be categorized as a risk factor for poor prognosis after acute coronary syndrome. Wed, 23 Apr 2014 01:14:23 UTC